期刊文献+

食管鳞状细胞癌组织中VASH1蛋白的表达 被引量:7

Expression of VASH1 protein in esophageal squamous cell carcinoma tissue
在线阅读 下载PDF
导出
摘要 目的:探讨血管生成抑制蛋白1(VASH1)在食管鳞状细胞癌(ESCC)组织中的表达及意义。方法:用免疫组化SP法检测112例ESCC和36例正常食管组织中VASH1的表达,对随访资料进行Kaplan-Meier生存分析和Cox回归分析。结果:VASH1蛋白在ESCC组织中的阳性表达率为76.8%(86/112),在正常组织中的阳性表达率为11.1%(4/36),差异有统计学意义(χ2=49.307,P<0.001);VASH1蛋白在ESCC组织中的表达与肿瘤浸润深度、淋巴结转移、TNM分期有关(P<0.05);Log-rank检验显示VASH1蛋白阳性表达ESCC患者的生存时间明显低于阴性表达者(χ2=9.547,P=0.002);Cox回归分析显示淋巴结转移、TNM分期及VASH1蛋白的表达可作为ES-CC预后的独立危险因素[RR(95%CI)=2.334(1.472~3.699)、2.109(1.428~3.326)、2.212(1.299~3.766)]。结论:VASH1可能在ESCC的发展、浸润、转移中起抑制作用。 Aim: To explore the expression of vasohibin 1(VASH1) in esophageal squamous cell carcinoma(ESCC). Methods:Immunohistochemistry was used to detect the expression of VASH1 in 112 cases of ESCC and 36 cases of normal e-sophageal tissue.Follow-up data were analyzed by Kaplan-Meier survival analysis and Cox regression analysis .Results:The positive rate of VASH1 protein in ESCC tissue was 76.8%(86/112), which was 11.1%(4/36), and the difference was statisti-cally significant (χ^2=49.307,P〈00.01 );the expression of VASH1 in ESCC tissue was significantly correlated with tumor depth of invasion, lymph node metastasis, and TNM stage( P〈0.05), log-rank test results showed that survival time of VASH1 posi-tive expression group was significantly lower than the negative expression group(χ^2=9.547,P=0.002);Cox regression analysis showed that lymph node metastasis, TNM stage and VASH1 expression can be used as an independent risk factor for prognosis of ESCC[RR(95% CI)=2.334(1.472-3.699),2.109(1.428-3.326),2.212(1.299-3.766)].Conclusion:VASH1 possibly plays a role in inhibiting development, invasion and metastasis of ESCC.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2014年第2期150-152,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 血管生成抑制蛋白1 食管肿瘤 鳞状细胞癌 预后 esophageal neoplasm squamous cell carcinoma prognosis
  • 相关文献

参考文献13

  • 1Weis SM,Cheresh DA. Tumor angiogenesis: molecular path- ways and therapeutic targets [ J ]. Nat Med, 2011,17 ( 11 ) : 1359.
  • 2Sato Y. The vasohibin family: a novel family for angiogen- esis regulation [ J ]. J Bioehem, 2013,153 ( 1 ) : 5.
  • 3Watanabe K,Hasegawa Y ,Yamashita H,et al. Vasohihin as an endothelium-derived negative feedback regulator of an- giogenesis [ J ]. J Clin Invest, 2004,114 ( 7 ) : 898.
  • 4Ahmed Z, Bieknell R. Angiogenic signalling pathways [ J ]. Methods Mol Biol,2009 ,467 :3.
  • 5Miyazaki Y, Kosaka T, Mikami S, et al. The prognostic sig- nificance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma [ J ]. Clin Cancer Res, 2012,18(15) :4145.
  • 6Kosaka T, Miyazaki Y, Miyajima A, et al. The prognostic significance of vasohibin-1 expression in patients with pros- tate cancer[J]. Br J Cancer,2013,108(10) :2123.
  • 7Tamaki K, Moriya T,Sato Y, et al. Vasohibin-1 in human breast carcinoma:a potential negative feedback regulator of angiogenesis [ J ]. Cancer Sci,2009,100 ( 1 ) : 88.
  • 8Shimizu K, Watanabe K, Yamashita H, et al. Gene regula- tion of a novel angiogenesis inhibitor, vasohibin, in endo- thelial cells [ J ]. Biochem Biophys Res Commun,2005,327 (3) :700.
  • 9Sato Y,Sonoda H. The vasohibin family: a negative regula- tory system of angiogenesis genetically programmed in en- dothelial cells [ J ]. Arterioscler Thromb Vase Biol,2007,27 (l) :37.
  • 10Kimura H,Miyashita H,Suzuki Y,et al. Distinctive localiza- tion and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis [ J ]. Blood,2009,113 ( 19 ) :4810.

同被引文献84

  • 1王珺,王欣彦,王敏,张淑兰.卵巢癌组织中Vasohibin基因表达与启动子区域甲基化的关系[J].中华肿瘤防治杂志,2006,13(22):1724-1727. 被引量:5
  • 2Kazi J U,Kabir N N,Flores M A,et al.SOCS proteins in regulation of receptor tyrosine kinase signaling[J].Cell Mol Life Sci,2014,71(17):3297-3310.
  • 3Vakiani E,Solit D B.KRAS and BRAF:drug targets and predictive biomarkers[J].J Pathol,2011,223(2):219-229.
  • 4Sjoquist K M,Burmeister B H,Smithers B M,et al.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.
  • 5Li G,Hu W,Wang J,et al.PhaseⅡstudy of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma[J].Int J Radiat Oncol Biol Phys,2010,78(5):1407-1412.
  • 6Llson D H,Kelsen D,Shah M,et al.A phaseⅡtrial of erlotinib in patients with previously treated squamous cell and adenocacinoma of the esophagus[J].Cancer,2011,117(7):1409-1414.
  • 7Canneliet P. Angiogenesis in heahh and disease [ J ]. Nat Med, 2003,9:653 - 660.
  • 8Kerbel RS. Tumor angiogenesis [ J ]. N Engl J Med, 2008,358 (19) :2039 -2049.
  • 9Kerbel RS. Vasohibin : The feedback on a new inhibitor of angiogen- esis[ J]. J Clin Invest,2004,114(7 ) :884 - 886.
  • 10Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as an en- dothelium derived negative feedback regulator of angiogenesis [ J ]. Clin Invest,2004,114 : 898 - 907.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部